Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 18/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26140596 | 0.82 | HRH3 (0.53) | HRH3KCNH2CYP2D6 | |
| SCHEMBL21738148 | 0.81 | HRH3 (0.43) | HRH3 | |
| SCHEMBL23583246 | 0.80 | HRH3 (0.41) | HRH3KCNH2CYP2D6 | |
| SCHEMBL21738156 | 0.80 | RECQL (0.35) | HRH3KCNH2MAPTPOLB | |
| SCHEMBL21738120 | 0.79 | HRH3 (0.43) | HRH3KCNH2CYP2D6 | |
| SCHEMBL21145998 | 0.77 | HRH3 (0.34) | HRH3KCNH2CYP2D6MAPT | |
| SCHEMBL26139029 | 0.77 | HRH3 (0.44) | HRH3KCNH2CYP2D6 | |
| SCHEMBL21738162 | 0.77 | HRH3 (0.38) | HRH3KCNH2CYP2D6MAPT | |
| SCHEMBL21738164 | 0.75 | MEN1 (0.41) | HRH3KCNH2CYP2D6MAPTPOLB | |
| SCHEMBL26139054 | 0.73 | HRH3 (0.49) | HRH3KCNH2CYP2D6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20220402910-A1 | THIADIAZOLE IRAK4 INHIBITORS | GILEAD SCIENCES, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11046686-B2 | Thiadiazole IRAK4 compounds | GILEAD SCIENCES, INC. (US) | 2021-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046686-B2 | Thiadiazole IRAK4 compounds | IRAK4, IRAK3, IRAK2 | HRH3 870/4885KCNH2 4282/4885CYP2D6 2635/4885 |
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | HRH3 932/4885KCNH2 4350/4885CYP2D6 2809/4885 |
| US-20220402910-A1 | THIADIAZOLE IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | HRH3 932/4885KCNH2 4350/4885CYP2D6 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.